An Open Label, Phase 1 Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Cenicriviroc (CVC)
Phase of Trial: Phase I
Latest Information Update: 13 May 2016
At a glance
- Drugs Cenicriviroc (Primary)
- Indications Graft-versus-host disease; Hepatic fibrosis; HIV-1 infections; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Tobira Therapeutics
- 13 May 2016 According to a Tobira Therapeutics media release, results from this trial were published in the journal Clinical Translational Science.
- 13 May 2016 Results published in the Tobira Therapeutics media release.
- 20 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History